Skip to main content

Table 2 Immunohistological assessment of metastases in antibody-treated and non-treated (control) HTM and TM

From: A novel rabbit derived anti-HER2 antibody with pronounced therapeutic effectiveness on HER2-positive breast cancer cells in vitro and in humanized tumor mice (HTM)

  9 weeks 21 weeks
HTM control HTM control HTM Trast HTM Pert HTM B100 p-value (control vs. B100) TM control TM B100 p-value (control vs. B100)
Lung 1/3 4/4 3/3 3/4 1/5 0.048 3/4 4/7 1
Liver 2/3 6/6 3/3 1/4
(p = 0.0333)
2/5 0.061 3/4 3/7 0.546
Brain 2/3 8/8 3/3 3/4 0/5 0.0008 3/4 2/7 0.242
  1. SK-BR-3 transplanted HTM and TM were immunohistologically stained using anti-HER2 antibodies in the lung, liver, and brain. HTM were analyzed in the age of 9 weeks (start of therapy) and in the age of ~ 21 weeks (end of therapy/experiment). The number of animals with detectable HER2-positive metastasis of the total number of animals (n/n) is indicated. Statistical differences were calculated using the two-sided Fisher’s exact test and significant differences are marked in italics